(R)-ketamine ameliorates the progression of experimental autoimmune encephalomyelitis in mice

Dextran sulfate sodium-induced inflammation and colitis in mice are ameliorated by (R)-ketamine, but not (S)-ketamine: A role of TrkB signaling

(2021) Yuko Fujita et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor

(2021) Yan Wei et al.   MOLECULAR PSYCHIATRY

Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability

(2021) Jordi Bonaventura et al.   MOLECULAR PSYCHIATRY

Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review

(2021) Jalal Dahham et al.   PHARMACOECONOMICS

Role of Gut Microbiota in Multiple Sclerosis and Potential Therapeutic Implications

(2021) Xu Wang et al.   Current Neuropharmacology

MicroRNAs, Multiple Sclerosis, and Depression

(2021) Hsiuying Wang   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

(R)-Ketamine attenuates LPS-induced endotoxin-derived delirium through inhibition of neuroinflammation

(2021) Jiancheng Zhang et al.   PSYCHOPHARMACOLOGY

Depression in multiple sclerosis: Is one approach for its management enough?

(2021) C. Danielle Jones et al.   Multiple Sclerosis and Related Disorders

TRPA1 involvement in depression- and anxiety-like behaviors in a progressive multiple sclerosis model in mice

(2021) Diulle Spat Peres et al.   BRAIN RESEARCH BULLETIN

The second brain: The connection between gut microbiota composition and multiple sclerosis

(2021) Melina Farshbafnadi et al.   JOURNAL OF NEUROIMMUNOLOGY

(R)-Ketamine ameliorates lethal inflammatory responses and multi-organ injury in mice induced by cecum ligation and puncture

(2021) Jiancheng Zhang et al.   LIFE SCIENCES

Intravenous arketamine for treatment-resistant depression: open-label pilot study

(2020) Gustavo C. Leal et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

A historical review of antidepressant effects of ketamine and its enantiomers

(2020) Yan Wei et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Risk of psychosis after repeated intermittent administration of (S)-ketamine, but not (R)-ketamine, in mice

(2020) Yunfei Tan et al.   JOURNAL OF AFFECTIVE DISORDERS

Maternal glyphosate exposure causes autism-like behaviors in offspring through increased expression of soluble epoxide hydrolase

(2020) Yaoyu Pu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Microglia in Multiple Sclerosis: Friend or Foe?

(2020) Brooke L. Guerrero et al.   Frontiers in Immunology

Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine

(2020) Kenji Hashimoto   BIOCHEMICAL PHARMACOLOGY

Structure, Function, and Regulation of the Blood-Brain Barrier Tight Junction in Central Nervous System Disorders

(2020) Jeffrey J. Lochhead et al.   Frontiers in Physiology

Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis

(2020) Anees Bahji et al.   JOURNAL OF AFFECTIVE DISORDERS

Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis

(2020) Jacqueline Nicholas et al.   ADVANCES IN THERAPY

RIP1 kinase inhibitor halts the progression of an immune-induced demyelination disease at the stage of monocyte elevation

(2019) Sitao Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine

(2019) Lijia Chang et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

(2019) Kenji Hashimoto   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model

(2019) Zhongwei Xiong et al.   BEHAVIOURAL BRAIN RESEARCH

Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites

(2019) Chun Yang et al.   Translational Psychiatry

Splenic NKG2D confers resilience versus susceptibility in mice after chronic social defeat stress: beneficial effects of (R)-ketamine

(2019) Kai Zhang et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Mechanistic Target of Rapamycin–Independent Antidepressant Effects of ( R )-Ketamine in a Social Defeat Stress Model

(2018) Chun Yang et al.   BIOLOGICAL PSYCHIATRY

The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis

(2018) Fengna Chu et al.   JOURNAL OF NEUROIMMUNOLOGY

Animal models of multiple sclerosis: Focus on experimental autoimmune encephalomyelitis

(2018) Ivana Bjelobaba et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of ( R,S )-ketamine and ( S )-ketamine, but not ( R )-ketamine

(2018) Zheng Tian et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

An update on ketamine and its two enantiomers as rapid-acting antidepressants

(2018) Kai Zhang et al.   Expert Review of Neurotherapeutics

Microglia in Central Nervous System Inflammation and Multiple Sclerosis Pathology

(2018) Sofie Voet et al.   TRENDS IN MOLECULAR MEDICINE

Antidepressant Potential of ( R )-Ketamine in Rodent Models: Comparison with ( S )-Ketamine

(2017) Kenichi Fukumoto et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model

(2017) Youge Qu et al.   Scientific Reports

Possible role of the gut microbiota–brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model

(2017) Chun Yang et al.   Translational Psychiatry

Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study

(2016) Jaskaran B. Singh et al.   BIOLOGICAL PSYCHIATRY

Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys

(2016) Kenji Hashimoto et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

(2016) Panos Zanos et al.   NATURE

Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine

(2016) Chun Yang et al.   PSYCHIATRY RESEARCH

Animal models of Multiple Sclerosis

(2015) Claudio Procaccini et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Gut Microbiota in Multiple Sclerosis

(2015) Brandi L. Cantarel et al.   JOURNAL OF INVESTIGATIVE MEDICINE

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects

(2015) C Yang et al.   Translational Psychiatry

The Benefits and Detriments of Macrophages/Microglia in Models of Multiple Sclerosis

(2013) Khalil S. Rawji et al.   Clinical & Developmental Immunology

Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)

(2011) Cris S Constantinescu et al.   BRITISH JOURNAL OF PHARMACOLOGY

Blood–brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE

(2010) Jami Bennett et al.   JOURNAL OF NEUROIMMUNOLOGY

Economic Burden of Multiple Sclerosis

(2010) Huseyin Naci et al.   PHARMACOECONOMICS